|
Mar 12
|
Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates
|
|
Mar 12
|
Nektar: Q4 Earnings Snapshot
|
|
Mar 12
|
Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates
|
|
Mar 12
|
Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Feb 24
|
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th
|
|
Feb 24
|
Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus
|
|
Feb 10
|
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
|
|
Jan 4
|
Institutional investors have a lot riding on Nektar Therapeutics (NASDAQ:NKTR) with 68% ownership
|
|
Sep 25
|
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
|
|
Jun 12
|
Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024
|
|
May 10
|
Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
|
|
May 10
|
Nektar Therapeutics (NKTR) First Quarter 2024 Earnings Overview
|
|
May 10
|
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
|
|
May 10
|
Q1 2024 Nektar Therapeutics Earnings Call
|
|
May 9
|
Nektar Therapeutics Reports First Quarter 2024 Financial Results
|
|
May 2
|
Nektar to Announce Financial Results for the First Quarter 2024 on Thursday, May 9, 2024, After Close of U.S.-Based Financial Markets
|
|
Apr 3
|
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
|
|
Mar 22
|
Nektar Management to Present at the H.C. Wainwright 2nd Annual Autoimmune & Inflammatory Disease Virtual Conference
|
|
Mar 6
|
Nektar (NKTR) Begins Phase IIb Study Rezpeg in Alopecia Areata
|
|
Mar 5
|
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
|